CCF

Question 1

What is the definition of Congestive Heart Failure (CHF)?

Answer 1

A complex and progressive disorder where Cardiac Output (CO) is inadequate to supply oxygen to meet the body’s metabolic demands, initially during exercise and ultimately at rest. It has a high mortality rate (~50% at 5 years).

Question 2

What are the primary pathophysiological types of Heart Failure?

Answer 2

1. Systolic Dysfunction (HFrEF): Impaired myocardial contraction, leading to ↓ Ejection Fraction (EF). 2. Diastolic Dysfunction (HFpEF): Impaired ventricular filling and relaxation due to hypertrophy and stiffening, with a preserved EF.

Question 3

List the main compensatory mechanisms activated in Heart Failure.

Answer 3

1. Activation of the Sympathetic Nervous System (SNS) 2. Activation of the Renin-Angiotensin-Aldosterone System (RAAS) 3. Myocardial Hypertrophy 4. Release of ADH (Vasopressin)

Question 4

What are the common clinical features (symptoms and signs) of CHF?

Answer 4

Symptoms: Shortness of breath, ↓ exercise tolerance, fatigue, cough. Signs: Tachycardia, peripheral/pulmonary edema, cardiomegaly, ascites, hepatomegaly, jugular venous distension (JVD).

Question 5

Differentiate between the NYHA Functional Classification and ACC/AHA Staging of Heart Failure.

Answer 5

NYHA: Classifies symptom severity (I-IV) based on physical activity. ACC/AHA: Stages the progression of the disease (A-D) from risk factors to refractory disease, focusing on development and prevention.

Question 6

What are the primary non-pharmacological management strategies for CHF?

Answer 6

1. Reduce cardiac workload (limit activity, bed rest in acute cases) 2. Dietary sodium restriction 3. Fluid restriction (in severe cases) 4. Weight monitoring

Question 7

What are the three main therapeutic goals of pharmacological management in CHF?

Answer 7

1. Alleviate Symptoms (e.g., dyspnea, edema) 2. Slow Disease Progression 3. Improve Survival (reduce mortality)

Question 8

List the major drug classes used in the pharmacological management of CHF.

Answer 8

1. Diuretics 2. Renin-Angiotensin System Inhibitors (ACEIs, ARBs) 3. Aldosterone Antagonists 4. Beta-Blockers (β-adrenoceptor antagonists) 5. Inotropic Agents 6. Vasodilators

Question 9

What is the role of Diuretics in CHF management?

Answer 9

They are used for symptomatic relief of fluid overload (e.g., pulmonary/peripheral edema) by reducing preload. They do not provide a mortality benefit and are used in combination with disease-modifying agents (ACEIs/ARBs, Beta-Blockers).

Question 10

Classify the diuretics used in CHF and state their primary site of action.

Answer 10

1. Loop Diuretics (e.g., Furosemide): Thick Ascending Limb of Loop of Henle. 2. Thiazide Diuretics (e.g., HCTZ): Early Distal Convoluted Tubule. 3. Potassium-Sparing (e.g., Spironolactone): Late Distal Tubule & Collecting Duct.

Question 11

What are the key side effects and a major caution for Furosemide?

Answer 11

Side Effects: Hypokalemia, ototoxicity (especially with rapid IV), hypomagnesemia, hyperuricemia. Caution: Sulfa allergy (as it is a sulfonamide derivative).

Question 12

Why are ACE Inhibitors considered cornerstone therapy in CHF?

Answer 12

They improve symptoms AND provide a mortality benefit by: 1. Reducing afterload (vasodilation) 2. Reducing preload (↓ aldosterone) 3. Retarding/Reversing pathological ventricular remodeling.

Question 13

What are the main side effects of ACE Inhibitors that may lead to discontinuation?

Answer 13

1. Dry, hacking cough (due to bradykinin accumulation) 2. Angioedema (a medical emergency) 3. Acute renal failure (in bilateral renal artery stenosis) 4. Hyperkalemia

Question 14

When are ARBs (Angiotensin Receptor Blockers) typically used in CHF?

Answer 14

As an alternative for patients who do not tolerate ACE inhibitors due to cough or angioedema. They do not inhibit bradykinin breakdown, so cough/angioedema are less common.

Question 15

What is the unique role of Aldosterone Antagonists (e.g.

Answer 15

Spironolactone

Question 16

What is the major risk associated with Aldosterone Antagonists and how is it managed?

Answer 16

Hyperkalemia. It is managed by: 1. Regular monitoring of serum potassium 2. Avoiding concurrent use of other K+-raising drugs (e.g., K+ supplements) 3. Using Eplerenone for less endocrine side effects (e.g., gynecomastia with Spironolactone).

Question 17

Why are Beta-Blockers

Answer 17

once contraindicated

Question 18

What is crucial to remember when initiating Beta-Blockers in a CHF patient?

Answer 18

Start with a very LOW dose and titrate up SLOWLY (“Start low, go slow”). Initial negative inotropic effect may cause temporary worsening of symptoms, but long-term benefits are profound.

Question 19

What is the role of sympathomimetic inotropes like Dobutamine in CHF?

Answer 19

They are used for SHORT-TERM, IN-HOSPITAL management of acute decompensated HF and cardiogenic shock. They provide positive inotropic support to increase cardiac output. Long-term use increases mortality due to arrhythmias.

Question 20

List the key pharmacokinetic properties of Dobutamine.

Answer 20

Onset of Action: Rapid (loading dose not required). Half-life: ~2 minutes. Administration: Continuous IV infusion (2-10 mcg/kg/min). Metabolism: Conjugated in the liver.

Question 21

What are the primary adverse effects of Dobutamine?

Answer 21

Cardiac: Tachycardia, arrhythmias. CNS: Anxiety, headache, tremor. Other: Can precipitate pulmonary edema. Tolerance develops with prolonged use.

Question 22

What is the role of Vasodilators like Hydralazine in CHF?

Answer 22

They are used to reduce afterload (arterial dilators) and preload (venous dilators), improving cardiac output. The combination of Hydralazine and Isosorbide Dinitrate is specifically beneficial in African-American patients with HFrEF.

Question 23

What is the Mechanism of Action of Hydralazine?

Answer 23

It causes direct relaxation of arterial smooth muscle, likely by promoting the release of Nitric Oxide (NO), leading to a reduction in systemic vascular resistance (afterload).

Question 24

What are the common side effects of Hydralazine?

Answer 24

Headache, flushing, tachycardia (reflex), palpitations, fluid retention, and a drug-induced Lupus-like syndrome with long-term use.

Question 25

What is the classic inotropic agent used in CHF

Answer 25

and what is its Mechanism of Action?

Question 26

Besides its inotropic effect

Answer 26

what other beneficial effects does Digoxin have in CHF?

Question 27

What is the most critical factor predisposing to Digoxin toxicity?

Answer 27

Hypokalemia. Low potassium levels increase the binding of Digoxin to the Na+/K+ ATPase pump, potentiating its toxic effects.

Question 28

List the signs and symptoms of Digoxin Toxicity.

Answer 28

Cardiac: Almost any arrhythmia (e.g., PVCs, AV block, bradycardia). Non-Cardiac: Anorexia, nausea, vomiting, diarrhea, visual disturbances (yellow-green halos, blurred vision), confusion, fatigue.

Question 29

What are the main contraindications and precautions for Digoxin?

Answer 29

Contraindications: Ventricular tachycardia, 2nd/3rd degree AV block (without a pacemaker). Precautions: Renal impairment, elderly, hypokalemia, hypothyroidism, hypercalcemia, concomitant use of amiodarone/verapamil.

Question 30

How is severe Digoxin toxicity treated?

Answer 30

1. Discontinue Digoxin. 2. Correct electrolyte imbalances (especially K+). 3. Administer Digoxin-specific Antibody Fragments (Digibind/Digifab) for life-threatening toxicity. 4. Use Atropine/pacing for bradyarrhythmias.

Question 31

For a patient with Hypertensive Heart Disease and CHF

Answer 31

what is the first-line drug class?

Question 32

What is the standard triple-therapy regimen for a patient with chronic HFrEF?

Answer 32

1. An ACEI (or ARB) 2. A Beta-Blocker (carvedilol, metoprolol, bisoprolol) 3. An Aldosterone Antagonist (spironolactone/eplerenone). A diuretic (e.g., furosemide) is added as needed for fluid overload.

Question 33

What is "cardiac remodeling" and which drug classes help reverse it?

Answer 33

Cardiac remodeling refers to the pathological changes in the heart's size, shape, and function after injury. ACEIs/ARBs, Beta-Blockers, and Aldosterone Antagonists are all disease-modifying agents that slow or reverse this process.